To provide additional educational opportunities at AMCP 2021, AMCP also allows non-commercial, grant-supported satellite symposia.
These learning activities are developed by medical education organizations and are an important part of the conference.
Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.
There is no fee for pre-registering for these educational activities, registration is for planning purposes only. You will receive information from the satellite host on how to access the virtual satellite platform. Satellites will not be accessible in the AMCP 2021 virtual event platform.
Monday, April 12 | 9-10:30am ET
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Pharmacy Times Continuing Education
- Supported by an independent educational grant from Biogen Inc.
- Continuing education credit available for Pharmacists, managed care professionals
- Contact hours: 1.5
Program Description
Before patients present with symptoms of Alzheimer disease (AD), neurons are affected due to inflammation and beta-amyloid plaques may accumulate. These plaques can often be observed with PET scans and allow for potential earlier diagnosis and therapeutic intervention. Beta-amyloid has been a focus of previous clinical trials, but research in tau antisense oligonucleotides and the protein ApoE4 in the setting of AD is expanding. Less than 5% of AD cases are considered to be the early-onset form, and early diagnosis may help improve patient quality of life and involvement in their care as well as decrease caregiver burden. To facilitate early identification of AD, managed care professionals and pharmacists must promote early identification of AD and include disease-modifying therapies into treatment protocols to preserve cognitive function in patients with AD. This interdisciplinary discussion will expand upon strategies presented at the AMCP 2020 Nexus conference that managed care professionals and pharmacists can use to collaborate to ensure guidelines for diagnosis and evaluation of AD and related dementias are incorporated into institutional management strategies.
Learning Objectives
- Review the clinical progression of Alzheimer disease (AD) and the value of biomarkers of disease in early diagnosis as they relate to treatment selection and patient management
- Analyze challenges in current treatment and management strategies in AD
- Classify clinical data for emerging disease-modifying therapies and their importance in early identification of disease
- Determine future managed care strategies that will allow for the uptake of future disease modifying therapies in AD
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Med-IQ
- This activity is supported by an educational grant from Pfizer Inc.
- The target audience is managed care pharmacists, pharmacy benefits managers, pharmacy directors, community pharmacists, specialty pharmacists, medical directors, health economics professionals, and other formulary and plan decision makers within managed healthcare organizations
- 1.5 contact hours for physicians and pharmacist
Program Description
This presentation reviews the impact of inflammatory skin conditions on clinical, psychosocial, and economic outcomes, specifically focusing on atopic dermatitis (AD) and alopecia areata (AA).
Coverage includes:
- Burden of more severe disease, and the relevance of associated comorbidities on severity and therapeutic selection
- Latest data on the pathophysiology of AD and AA as chronic, systemic inflammatory conditions and the role of the JAK-STAT pathway as a prime therapeutic target
- Overview of emerging JAK inhibitors (mechanisms of action, safety, efficacy, dosing, administration, etc.) in AD and AA
- Clinical and cost implications of new and emerging JAK inhibitors in formulary placement and benefits design
The session will end with an opportunity for Q&A and discussion.
Program Manager
Whitney Hess
Med-IQ
whess@med-iq.com
Monday, April 12 | 11am-12:30pm ET
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Pharmacy Times Continuing Education
- Supported by an independent educational grant from Mitsubishi Tanabe Pharma America, Inc.
- Continuing education credit available for Pharmacists, managed care professionals
- Contact hours: 1.5
Program Description
Patients with amyotrophic lateral sclerosis (ALS) experience progressively worsening physical function. Disruption of upper and lower motor neurons are involved in ALS, with lower motor neurons found in the spinal cord and brain stem and upper motor neurons in the motor cortex. The time from symptom onset to diagnosis can be up to 1 year, and by the time patients receive a diagnosis, nearly 50% to 70% of motor neurons have been impaired. Pharmacists can promote earlier treatment, which has shown to delay progression in some patients, and can encourage clinicians to increase efforts for early identification with screening tools and treatment guidelines. It is currently recommended that both approved drugs, riluzole and edaravone, be prescribed for all patients with ALS regardless of stage or condition, provided there are no contraindications for their use. Gene-based approaches to disease-modifying drugs are currently under investigation, with promising results in slowing the progression of ALS. Pharmacists are well positioned to assess emerging therapy options and can collaborate with managed care professionals to develop treatment protocols as new data and treatments become available.
Learning Objectives
- Explore the economic burden of amyotrophic lateral sclerosis (ALS) treatment and management as well as the severe impact on patient quality of life
- Examine the most recent real-world and clinical data for currently available and investigational agents for the management of ALS
- Apply recent data and scientific advances to drug utilization management strategies
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by DKBmed in conjunction with AMCP
- Supported by independent educational grants from Regeneron and Sanofi
- The target audience includes pharmacists, managed care pharmacists, medical directors, pharmacy directors, pharmacy benefit managers, and other formulary decision-makers involved in the management and decision-making process for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
- Contact hours: 1.5
Program Description
Unfortunately, conventional treatments don’t provide long-term relief for all patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). For many patients who suffer from this conditon, symptoms include nasal congestion, pain, discomfort and a loss of sense of smell, all of which significantly impair quality of life for millions of suffering patients. This program combines expert faculty presentations along with real patients sharing their stories and covers the patient burden, the pitfalls of current treatments, and the role of biologics in long-term treatment for eligible patients.
Learning Objectives
- Describe the financial and medical burden faced by patients with chronic rhinosinusitis with nasal polyps.
- Identify challenges present in conventional treatment options for CRSwNP.
- Evaluate the role of monoclonal antibodies in CRSwNP treatment and define currently available and in-development biologics for CRSwNP.
Program Manager
Faith Rogers
DKBmed
frogers@dkbmed.com
Monday, April 12 | 1-2:30pm ET
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Pharmacy Times Continuing Education
- Supported by an independent educational grant from from Bristol Myers Squibb, Kite Pharma, Inc. and from Novartis Pharmaceuticals Corporation
- Continuing education credit available for Pharmacists, Managed Care
- Contact hours: 1.5
Program Description
A number of factors have contributed to the widespread use of chimeric antigen receptor-modified (CAR) T-cell therapy in the treatment of B-cell malignancies. However, increased utilization of CAR T-cell therapies comes with unique considerations for managed care professionals and requires pharmacists to collaborate with the multidisciplinary team to manage CAR T-cell–associated adverse effects. Despite the neurological toxicities, CAR T-cell therapies have shown significant improvement in cost-benefit compared with traditional chemotherapy. Potential economic benefits have spurred discussions about earlier initiation of CAR T-cell therapy in treatment algorithms, which could improve overall survival in patients with aggressive B-cell malignancies. To facilitate access to these treatments, managed care professionals and the healthcare team must work together to standardize processes for the integration of CAR T-cell therapies into clinical practice and determine optimal payment modalities to increase access for patients to improve outcomes. The panel members leading this discussion will address safety and cost considerations for the incorporation of CAR T-cell therapies into the treatment landscape of patients with B-cell malignancies.
Learning Objectives
- Interpret recent data for approved and emerging chimeric antigen receptor-modified (CAR) T-cell therapies and the impact of these treatments on the future paradigm of cancer care
- Analyze the costs of treatment as well as the value associated with CAR T-cell therapy
- Investigate strategies to improve management of costs and access to treatment associated with CAR T-cell therapy
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Pharmacy Times Continuing Education
- This activity is supported by educational grants from Takeda Pharmaceuticals U.S.A., Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
- Continuing education credit available for Pharmacists, Managed Care
- Contact hours: 1.5
Program Description
Inflammatory bowel disease (IBD) presents with gastrointestinal inflammation and symptoms including diarrhea, abdominal pain, rectal bleeding, and weight loss. These symptoms, as well as other complications of disease, can have a significant impact on a patient’s quality of life and contribute to substantial economic burden. New guidance for the treatment of IBD focuses on the use of biologics and small molecules to maintain remission of IBD, thereby reducing hospitalizations and use of adjuvant agents to manage IBD exacerbations. As members of the multidisciplinary team, managed care pharmacists must be involved in a coordinated approach to the treatment and management of patients with IBD. They can use their knowledge of emerging data for targeted immune modulators and Janus kinase inhibitors to develop appropriate patient management strategies according to the most recent guidelines and facilitate their inclusion in clinical practice. This activity will further explore the patient-clinician relationship through video clips of a patient with IBD detailing their experience from diagnosis to initiation of treatment and working to manage costs of treatment with their healthcare team.
Learning Objectives
- Discuss the incidence and pathophysiology of IBD as well as the burden and challenges associated with IBD management.
- Examine the safety and efficacy data of current and emerging treatments for IBD, including their mechanism of action, dosing and adverse effects.
- Identify various treatment strategies that managed care professionals can implement to help improve patient adherence, clinical outcomes, and decrease healthcare costs associated with IBD.
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Monday, April 12 | 6:30-8pm ET
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Pharmacy Times Continuing Education
- Supported by an independent educational grant from AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme Corp.
- Continuing education credit available for Pharmacists, Managed Care
- Contact hours: 1.5
Program Description
Patients with ovarian cancer with advanced disease or residual disease or those who undergo multiple rounds of platinum-based chemotherapy are at risk for decreased survival and increased disease resistance. The incorporation of PARP inhibitors into the treatment paradigm of ovarian cancer represents an opportunity to meet unmet needs in the treatment and maintenance of this disease. While clinical studies have demonstrated positive outcomes, economic analyses have presented considerable variations in the cost-effectiveness of PARP inhibitors across cancer types, including ovarian cancer. Managed care professionals and pharmacists must navigate a delicate balance between access to and utilization of PARP inhibitors in ovarian cancer. The financial implications of the use of oral oncolytics remains a significant challenge, limiting affordability and patient access. This discussion will address care delivery and payment models between payers, health systems, and pharmacies, and steps these entities can take to facilitate patient access to oral oncolytics such as PARP inhibitors.
Learning Objectives
- Identify emerging trends in the clinical use of PARP inhibitors for the treatment of ovarian cancer.
- Explain how the recent trends in use of PARP inhibitors will impact the cost of caring for patients with ovarian cancer.
- Explore challenges affecting patient access to oral oncolytics such as PARP inhibitors.
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Impact Education, LLC.
- Supported by an independent educational grant from Dexcom, Inc.
- The primary target audience for this activity consists of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending the AMCP 2021 Managed Care and Specialty Pharmacy Annual Meeting
- Contact hours: 1.5
Program Description
Diabetes remains a leading cost driver for payers and employers, characterized by insulin spend, hospitalization, and ER utilization. System-wide incentives to prescribe and access real-time continuous glucose monitoring (rtCGM) aligns with a patient-centered approach for managing diabetes-related outcomes and costs.
Pharmacy benefit coverage and access for CGM for appropriate sub-populations can confer immediate cost savings via channel efficiencies and lower acquisition costs. Furthermore, rtCGM has the potential to improve diabetes-specific performance and outcome measures in members with type 1, type 2, and gestational diabetes.
Learning Objectives
- Characterize the value of health technology and remote patient monitoring as part of a comprehensive management strategy for diabetes to improve glycemic outcomes
- Discuss the positive impact of pharmacy coverage on payer management interventions, provider administrative burden, member experience and access, and overall cost of care
- Review the potential of rtCGM to improve diabetes performance measures via hypoglycemia risk reduction, improved HbA1c, and reduced resource utilization with case scenarios (e.g., pregnancy; senior populations)
Program Manager
Steve Casebeer
Impact Education, LLC.
steve.casebeer@impactedu.net
Tuesday, April 13 | 6:30-8pm ET
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by PRIME Education, LLC
- Supported by an independent educational grant from Mycovia Pharmaceuticals, Inc.
- Continuing education credit available for Managed care pharmacists, physicians, and nurses
- Contact hours: 1.5
Program Description
Vulvovaginal candidiasis (VVC) affects an estimated 70% of women worldwide, with 10% suffering recurrent VVC (RVVC). Despite the prevalence of RVVC, there remains a lack of awareness of its impact on quality of life and of effective treatment options. Fortunately, novel therapies in late stages of development are poised to advance outcomes for women with RVVC.
In this accredited live virtual symposium, experts in RVVC and managed care explore the often-overlooked physical, psychosocial, and economic impacts of RVVC. They will review current and evolving management strategies, interpret the latest clinical data for the first-ever therapies in development specifically for RVVC, and discuss managed care strategies to deliver evidence-based and patient-centered care.
Don't miss:
- The latest developments in novel therapies
- Current insights on the broad impact of RVVC on quality of life
- Managed care strategies to support RVVC patient care
Learning Objectives
- Evaluate the burden that recurrent vulvovaginal candidiasis (RVVC) imposes on women, including impacts on quality of life and productivity
- Differentiate the efficacy and safety profiles of emerging treatments for RVVC from the current standard of care
- Apply key trial data to develop managed care and specialty pharmacy frameworks that ensure patient-centered RVVC treatment and management
Program Manager
Samantha Hoffman
PRIME Education, LLC
meetingsolutions@primeinc.org
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Pharmacy Times Continuing Education
- Supported by an educational grant from Acadia Pharmaceuticals
- Continuing education credit available for Pharmacists, managed care professionals
- Contact hours: 1.5
Program Description
Older adult patients with dementia-associated psychosis may experience delusions and hallucinations and exhibit agitation or aggression towards others. Current guideline recommendations for care of patients with dementia-related psychosis gives preference to nonpharmaceutical interventions, with antipsychotics reserved for use with patients experiencing severe symptoms to reduce risk of harm to themselves or others. Inappropriate use of antipsychotics for patients with dementia-related psychosis conveys safety and administration risks for older adults, which can increase direct costs to both patients and the healthcare system. Managed care professionals need to be up-to-date with clinical data associated with current and emerging therapies and should review management strategies regularly. This activity will also review the impact of dementia-related psychosis on patients and caregivers.
Learning Objectives
- Explain the clinical presentation of dementia and the high rate of psychosis in this population as well as its effect on patients and caregivers
- Compare existing off-label use of first- and second-generation antipsychotic medications for dementia-related psychosis, including their risks and benefits
- Analyze the clinical trials for the new class of drug therapy for dementia-related psychosis
- Optimize the role of managed care professionals in developing an evidence-based access strategy that integrates a new class of drugs for dementia-related psychosis treatment
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Wednesday, April 14 | 6:30-8pm ET
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by CME Outfitters, LLC
- Supported by an independent educational grant from Biogen Idec MA, Inc.
- Continuing education credit available for pharmacists and physicians
- Contact hours: 1.5
Program Description
Although a rare disease, spinal muscular atrophy (SMA) is nevertheless the most common fatal genetic disease of infancy. In order to optimize patient outcomes in SMA, evidence-based, managed care decision-making is critical. The virtual symposium will open a dialogue between providers and managed care professionals in order to develop evidence-based strategies to improve access for patients with SMA who are likely to benefit from new and emerging therapies.
Learning Objectives
- Determine the tests and clinical assessments that can aid in diagnosing SMA as well as monitoring disease activity and treatment response.
- Apply the latest clinical evidence to evaluate the cost-effectiveness of approved and emerging therapies for SMA.
- Recognize the individual patient- and parent-/caregiver-related factors that guide clinical decision-making in SMA management.
Program Manager
CME Outfitters, LLC
webmaster@cmeoutfitters.com
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Pharmacy Times Continuing Education
- Supported by an independent educational grant from Amgen
- Continuing education credit available for pharmacists, managed care
- Contact hours: 1.5
Program Description
Recently, there have been some changes and promising new results in the area of AML treatment. Updated indications for existing therapies and recent approvals have resulted in increased therapeutic options for AML patients. New maintenance therapy regimens for AML, which have demonstrated clinical benefit in recent studies, may soon be available. While treatment of older AML patients is still a significant challenge, new therapeutic options and recommendations present options that managed care pharmacists should be aware of. AML leads to significant healthcare utilization driven by hospitalizations, intensive care admissions, and chemotherapy drug costs. Hospitalizations are the largest cost drivers in patients with AML accounting for an estimated 66% to 92% of total costs. (Sacks 2018) These costs are widely variable according to the treatment approach, insurance status, and other patient-related factors. It will be critical for managed care pharmacists to stay informed about available agents which promise to improve patient outcomes within a context of cost-effectiveness.
Learning Objectives
- Examine new approvals and recent clinical updates to investigational therapies for the treatment of AML
- Identify maintenance regimens with hypomethylating agents and the results from recent clinical trials with these regimens
- Identify challenges associated with treatment of older AML, particularly during the COVID-19 pandemic
- Outline the key criteria and factors for optimal clinical pathway development, implementation, and use in treatment of patients with AML
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
Thursday, April 15 | 6:30-8pm ET
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Pharmacy Times Continuing Education
- Supported by an educational grant from AstraZeneca
- Continuing education credit available for pharmacists, managed care
- Contact hours: 1.5
Program Description
Anemia is a common complication of chronic kidney disease (CKD), with symptoms including fatigue, weakness, headaches, dizziness, and difficulty breathing or shortness of breath. Current standards of care for anemia related to CKD are iron supplementation, blood transfusions, or erythropoiesis-stimulating agents (ESAs). Patients with CKD have several comorbid conditions, with cardiovascular disease being the most common, which complicates treatment decisions in some patients as treatment with ESAs carry risk of cardiovascular toxicity. Novel treatment mechanisms target hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase inhibitors to treat anemia in patients with CKD whether they are dialysis-dependent or not as well as those who are at risk for cardiovascular events. As new treatments such as these enter the treatment paradigm of CKD-related anemia, managed care professionals must understand potential complications and the role of these new agents in lowering disease burden for patients and healthcare resource utilization for payers. This activity includes the perspective of a caregiver and patient with CKD-related anemia who will share their experience with this disease highlighting the burden of disease exacerbations and how this condition has affected their quality of life.
Learning Objectives
- Determine the relationship of inflammation and anemia, as well as the role of hepcidin and other pathophysiology in chronic kidney disease (CKD)-related anemia
- Identify the current standards of care and current challenges treating anemia in CKD
- Apply hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase inhibitors to treat anemia in dialysis-dependent and non–dialysis-dependent CKD
- Examine how new treatments can benefit current healthcare burden and quality of life for patients who have anemia in CKD
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Med Learning Group
- This is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals
- This CME initiative is designed to meet the educational needs of U.S.-based managed care professionals who manage patients with moderate-to-severe asthma
- Contact hours: 1.0
Program Description
A 1.0 hour cased-based, Mixed Reality (Whiteboard & 2D/3D animations) Satellite Symposium at the Academy of Managed Care Pharmacy (AMCP) Managed Care and Speciality Pharmacy Annual Meeting 2021 with a.) Interactivity: Attendees will be able to foster communications via polling, Q&A, and ARS; b.) Whiteboard & 2D/3D Animation Experiences: There will be whiteboard and 2D/3D animation experiences during the symposium and these will also be made available for download.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Discuss the patient and healthcare system burdens associated with asthma;
- Explain how the underlying molecular pathophysiology of moderate-to-severe asthma informs targeted biologic therapies;
- Apply current medical committee guidelines and recommendations for the management of patients with moderate-to-severe asthma in clinical practice; and
- Utilize findings from clinical trials of biologic therapies as add-on treatments in the maintenance setting for patients with moderate-to-severe asthma.
Program Manager
Felecia Beachum
Med Learning Group
fbeachum@medlearninggroup.com
Friday, April 16 | 9-10:30am ET
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Impact Education, LLC.
- Supported by independent educational grants from Novo Nordisk and uniQure
- The primary target audience for this activity consists of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of the AMCP, and other managed health care professionals attending the AMCP 2021 Managed Care and Specialty Pharmacy Annual Meeting.
- Contact hours: 1.5
Program Description
The management of hemophilia is complex; however, appropriate management is vital to minimizing and/or preventing complications that contribute to worse health outcomes and higher health care resource utilization. Education is needed to operationalize and implement well-coordinated patient management, the most cost-effective ways of using available treatments, and the importance of collaboration among all stakeholders, which includes leveraging the success of the comprehensive care model utilized by hemophilia treatment centers (HTCs).
Learning Objectives
- Describe recent insights into the safety, efficacy, and unique attributes of recently approved and emerging hemophilia treatment options
- Assess the integration of the evolving treatment paradigm within the current hemophilia treatment algorithm
- Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences
- Apply processes for managed care and specialty pharmacy professionals to improve communication and collaboration with HTCs
Program Manager
Steve Casebeer
Impact Education, LLC.
steve.casebeer@impactedu.net
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by CMEducation Resources
- Supported by an independent educational grant from Abbott Diabetes Care
- Continuing education credit available for pharmacists operating within a managed care environment, physicians, nurses, PAs, diabetes educators
- Contact hours: 1.5
Program Description
This managed care initiative will focus on emerging digital, real time-, and sensor patch-based technologies for continuous monitoring of glucose levels, to improve drug interventions for persons with diabetes, minimize risks of hypoglycemia, maximize time in target range for blood glucose, and to optimize treatment interventions and drug titration and selection in the managed care environment. The program content will discuss and communicate the evidentiary basis for patch-based CGM technologies, as well as strategies for how diabetes-focused managed care pharmacists should communicate, collaborate, and implement CGM-based technologies into their overall diabetes care plans; and. advise and educate patients on CGM-based methods that can be employed on a patient-centric basis and/or in conjunction with their HCP. In addition, the expert faculty and the program agenda will focus on:
- How to interpret the glucose metrics report (AGP) generated by sensor-based glucose-monitoring technology: Implications for real world diabetes care in the managed care/HMO setting
- Pharmacoeconomic outcomes and cost analyses associated with sensor-based glucose monitoring (CGM) in persons with diabetes: Focus on implications for managed care formularies and clinical diabetes programs
- Reduction in hospitalizations for DKA in persons with diabetes employing CGM: Implications for managed care pharmacists and physicians, and analyses of potential cost savings
- Reduction in hospitalizations for hypoglycemia in persons with diabetes employing CGM: Implications for managed care pharmacists and physicians, and analyses of potential cost savings across the spectrum of diabetes care
- Clinical triggers and phenotypes that benefit from sensor-based CGM: Improving metabolic (TIR, eA1c, and GMI) metrics to reduce short- and long-term complications and costs associated with diabetes
- Role of sensor-based glucose monitoring in persons with type 2 diabetes on oral antidiabetic drugs: improvements in
Learning Objectives
- Outline and discuss the evidentiary basis for senor/patch-based CGM technologies, and how to best Implement CGM-based technologies into their overall diabetes care plans for persons with T1D and T2D within the managed care environment
- Analyze the rationale and evidence for recommending and facilitating adoption of technology-centric CGM monitoring and treatment plans using patch-and-reader-based technologies.
- Compare and contrast available CGM-facilitating monitoring technologies and pair such technologies with optimal patient profiles.
- Educate persons with diabetes, within the managed care environment, about the rationale, evidence, and outcome- optimizing results associated with technology-based, patient-centric and physician-directed CGM monitoring strategies that can be used to effect optimal lifestyle, diet-, and pharmacology-based approaches to attaining guideline-based HA1c levels in persons with T1D and T2D.
- Identify which persons with diabetes are ideal candidates for a technology-based care
Program Manager
Milo Falcon
CMEducation Resources
milo.falcon@pharmatecture.net
Friday, April 16 | 1-2:30pm ET
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Pharmacy Times Continuing Education
- Supported by educational grants from Astellas and Seagen Inc., formerly Seattle Genetics.
- Continuing education credit available for Pharmacists, managed care
- Contact hours: 1.5
Program Description
Urothelial cancer (UC) is the most common type of bladder cancer and can involve the bladder, ureter, and renal pelvis. Platinum-based chemotherapy is the mainstay of treatment for locally advanced or metastatic UC (mUC). In patients who are unable to tolerate platinum agents or whose tumors express PD-L1, checkpoint inhibitors have a significant role. After first-line therapy, multiple advancements including use of maintenance therapy, indications for antibody-drug conjugates and targeted approaches, and growth of evidence for use immune checkpoint inhibitors in the second-line setting have changed the treatment landscape. Multiple investigational approaches incorporating novel agents and combination therapy approaches are rapidly evolving. A further consideration is the economic burden of treatment with chemotherapy, checkpoint inhibitors, and emerging agents and treatment-related adverse effects. This panel will focus on the growth of therapies for this disease, challenges, and solutions to optimize overall patient outcomes.
Learning Objectives
- Analyze the current standard treatment options for locally advanced or metastatic urothelial cancer (mUC) and evidence-based recommendations for their use
- Differentiate the efficacy, safety, and place in therapy of emerging treatment options and investigational combination therapies in locally advanced/mUC
- Explore the economic burden of bladder cancer and impact on health-related quality of life
- Examine the cost-effectiveness of standard, new, and emerging therapies for bladder cancer and their impact in patient management
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Creative Educational Concepts
- Supported by an independent educational grant from American Regent
- Continuing education credit available for Pharmacists and Physicians
- Contact hours: 1.5
Program Description
This adaptive educational activity is targeted to managed care professionals, physicians, and specialty pharmacists attending the 2021 Academy of Managed Care Pharmacy (AMCP) Annual Meeting. Activity attendees will be given the opportunity to virtually interact with world-renowned expert faculty across all clinically relevant aspects of iron deficiency (ID) management in the setting of comorbid heart failure (HF). The session will begin with a thorough review of the pathophysiologic underpinnings of ID in HF, specifically the role of hepcidin in hyperinflammatory states and the subsequent implications on iron supplementation approaches. The robust prognostic implications and outcomes manifestations of ID in HF, including functional capacity, quality of life, and morbidity and mortality will also be reviewed in detail as a means of providing a foundational knowledge base. In the remainder of the educational session, activity attendees will appraise existing and emerging clinical trial data of IV iron therapies for ID in HF, and then provide a dynamic, case-based opportunity for attendees to apply the information they have learned into real-world clinical scenarios. Lastly, attendees will get to pilot our innovative guidance flowchart as an educational resource and clinical tool for managing ID in HF. All clinical aspects of this presentation will be augmented with cost considerations and implications at every level, allowing for a relevant and impactful educational experience for patient-facing and non-patient-facing clinicians and managed care professionals alike.
Learning Objectives
- Discuss the basic principles of iron metabolism and absorption, with a focus on how these principles apply to treatment.
- Understand the complex pathophysiology underlying iron deficiency (ID), even in the absence of concomitant anemia, with particular emphasis on the role of hepcidin, on heart failure (HF) outcomes and iron supplementation strategies.
- Recognize the robust impact of comorbid ID and HF, and describe the practical prognostic manifestations of ID on patient functional capacity, quality of life, and morbidity and mortality outcomes.
- Review the essential utility of serum ferritin and transferrin saturation (TSAT) as diagnostic laboratory indices for ID, and implement the diagnose, treat-to-target, and rapid reassessment cycle into practice.
- Differentiate the practical distinctions between functional and absolute iron deficiency.
- Appraise existing, ongoing, and planned clinical trials of IV iron therapies for ID in HF, and identify pivotal trials that have influenced current practice and consensus guidelines for ID management in HF (ESC and AHA).
Program Manager
Ashley C. Lilly, MHA
Creative Educational Concepts
alilly@ceconcepts.com
Friday, April 16 | 6:30-8pm ET
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Med Learning Group
- Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
- This activity is intended for managed care pharmacists, physicians, and other healthcare professionals involved in the management of patients with moderate-to-severe atopic dermatitis.
- CME/PharmD/CNE: 1.0
Program Description
Join Peter Lio, MD and Geoffrey Wall, PharmD in this interactive, case-based program about the underlying causes and treatments of atopic dermatitis. Through the use of 2D and 3D animations, this program aims to engage pharmacists and other atopic dermatitis caregivers by studying disease pathophysiology and how treatment options work. In the past few years, there have been interesting therapeutic developments in current and emerging systemic agents as part of the overall treatment plan, the knowledge of which can help improve standards of care for this disease.
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Learning Objectives
- Recognize patient-specific factors that influence the selection of therapies for the management of moderate-to-severe atopic dermatitis, including comorbidities, adherence barriers, disease severity, and quality-of-life issues
- Evaluate clinical trial data on the efficacy and safety of systemic and topical treatments for the management of moderate-to-severe atopic dermatitis
- Identify strategies to manage healthcare costs while improving quality-of-life for patients with atopic dermatitis
- Develop treatment plans that apply evidence-based medication use strategies to enhance outcomes in patients with moderate-to-severe atopic dermatitis
Program Manager
Ashley Whitehurst
Med Learning Group
awhitehurst@medlearninggroup.com
This session is now concluded. For additional CPE-related information or for the recording of this session, please contact the satellite program manager at the contact info listed below.
- Provided by Pharmacy Times Continuing Education
- Supported by an educational grant from Biogen
- Continuing education credit available for Pharmacists, managed care professionals
- Contact hours: 1.5
Program Description
Spinal muscular atrophy (SMA) is a common fatal genetic disease, and affects Caucasian populations and males at higher rates compared with African American and Hispanic populations or females. A deficiency in SMN protein causes irreversible degeneration of motor neurons, which manifests as progressive muscle weakness resulting in patients having difficulty moving, swallowing, or breathing. SMA can quickly progress to complications affecting breathing and swallowing functions, leading to patients needing specialized care with ventilators and/or feeding tubes. Recently approved disease-modifying therapies and emerging treatments have the potential to change SMA treatment protocols as well as improve the quality of life for patients and caregivers. This interdisciplinary discussion will expand upon strategies presented at the AMCP 2020 Nexus conference that managed care professionals and pharmacists can use to collaborate to ensure guidelines for early diagnosis and evaluation of SMA are incorporated into institutional management strategies.
Learning Objectives
- Identify current treatment challenges in spinal muscular atrophy (SMA), burden of the disease, and the need for early intervention
- Analyze old and new treatment standards along with the most current data and new clinical trials that aid in the advancement of treatment protocols for patients with SMA
- Construct opportunities for future strategies that will allow increased access to treatment for patients with SMA
Program Manager
Crissy Wilson
Pharmacy Times Continuing Education
cwilson@pharmacytimes.com